Bristol-Myers Squibb Co (NYSE:BMY) Shares Sold by Wesbanco Bank Inc.

Wesbanco Bank Inc. cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 409,471 shares of the biopharmaceutical company’s stock after selling 3,874 shares during the period. Bristol-Myers Squibb makes up about 0.9% of Wesbanco Bank Inc.’s portfolio, making the stock its 23rd largest holding. Wesbanco Bank Inc.’s holdings in Bristol-Myers Squibb were worth $18,570,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. James Investment Research Inc. lifted its stake in Bristol-Myers Squibb by 36.5% in the 1st quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 219 shares in the last quarter. Lowe Brockenbrough & Co. Inc. raised its position in shares of Bristol-Myers Squibb by 0.5% during the 1st quarter. Lowe Brockenbrough & Co. Inc. now owns 43,384 shares of the biopharmaceutical company’s stock valued at $2,070,000 after buying an additional 220 shares during the period. Squar Milner Financial Services LLC raised its position in shares of Bristol-Myers Squibb by 5.6% during the 1st quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 223 shares during the period. EP Wealth Advisors LLC raised its position in shares of Bristol-Myers Squibb by 5.4% during the 1st quarter. EP Wealth Advisors LLC now owns 4,669 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 240 shares during the period. Finally, Sunbelt Securities Inc. raised its position in shares of Bristol-Myers Squibb by 4.4% during the 2nd quarter. Sunbelt Securities Inc. now owns 5,830 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 246 shares during the period. Hedge funds and other institutional investors own 80.27% of the company’s stock.

Several research firms have recently commented on BMY. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price target on the stock. in a research report on Monday, May 20th. ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Monday, August 26th. Bank of America lifted their price target on shares of Bristol-Myers Squibb from $46.00 to $49.00 and gave the company a “neutral” rating in a research report on Tuesday, September 3rd. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research report on Thursday, June 13th. Finally, Goldman Sachs Group assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price for the company. One analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $55.74.

Bristol-Myers Squibb stock traded down $0.18 during trading on Friday, hitting $49.43. The company had a trading volume of 332,722 shares, compared to its average volume of 9,503,818. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $63.69. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. The company’s 50 day simple moving average is $46.87 and its 200-day simple moving average is $47.14. The stock has a market cap of $81.44 billion, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 2.39 and a beta of 0.70.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same quarter last year, the firm earned $1.01 EPS. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. As a group, analysts forecast that Bristol-Myers Squibb Co will post 4.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.41 dividend. The ex-dividend date is Thursday, October 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.32%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the completion of the purchase, the director now directly owns 11,397 shares in the company, valued at approximately $509,673.84. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Candlestick

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.